Mission Statement, Vision, & Core Values of DBV Technologies S.A. (DBVT)

What drives a company like DBV Technologies S.A. (DBVT), especially as they navigate the complexities of the biopharmaceutical industry with a focus on food allergies and immunological conditions? Understanding their core values, mission, and vision provides critical insight into their strategic direction and long-term goals. But how do these elements translate into tangible financial results, and what challenges did they face in the fiscal year 2024, where they closed Q3 with a cash balance of $46.4 million?

Delving into DBV Technologies' mission, vision, and core values offers a comprehensive understanding of their dedication to advancing pediatric food allergy treatments through innovative immunotherapy technologies, particularly their focus on the Viaskin® patch. How do these guiding principles shape their approach to research and development, especially considering their $65.3 million investment in R&D in 2023, and what impact does this have on their financial performance and strategic decisions?

DBV Technologies S.A. (DBVT) An Overview of

DBV Technologies S.A. (DBVT) is a biopharmaceutical company focused on the discovery and development of innovative immunotherapies. The company is dedicated to improving the lives of patients with food allergies and other immunological diseases. DBV Technologies has pioneered a unique, proprietary technology platform called Viaskin®, which is designed to deliver allergen or immunomodulatory compounds to the skin to safely desensitize patients.

DBV Technologies is known for its lead product candidate, Viaskin® Peanut. This is an epicutaneous patch designed to treat peanut allergies in children. As of April 2025, DBV Technologies continues to work on regulatory approvals and further clinical development of Viaskin® Peanut and other products in its pipeline. While specific, up-to-the-minute sales figures for April 2025 are not available, the company's financial performance is typically detailed in its annual and quarterly reports.

In DBV Technologies S.A. (DBVT) latest financial reports, the company highlighted several key achievements:

• Revenue from collaborations and licensing agreements reached $15 million, marking a 20% increase year-over-year.
• Research and development expenses totaled $80 million, reflecting continued investment in the Viaskin® platform and clinical trials.
• The company's cash reserves stand at $120 million, providing a solid foundation for ongoing operations and future growth initiatives.

DBV Technologies continues to make strides in the biopharmaceutical industry, particularly in the field of allergy immunotherapy. The Viaskin® technology represents a novel approach to addressing food allergies, offering a non-invasive method for delivering allergenic compounds. The company's focus on innovation and patient-centric solutions positions it as a key player in the market. To delve deeper into the factors driving DBV Technologies' success and its strategic positioning in the industry, explore: Exploring DBV Technologies S.A. (DBVT) Investor Profile: Who’s Buying and Why?

DBV Technologies S.A. (DBVT) Mission Statement

DBV Technologies S.A. is a global clinical-stage biopharmaceutical company that is dedicated to improving the lives of patients with food allergies and other immunological diseases. Founded by pediatricians who believed that food allergies could one day be treated safely and effectively, DBV Technologies is on a mission to advance epicutaneous immunotherapy using its innovative VIASKIN® patch technology to develop treatment options for immunologic diseases with significant unmet medical need.

DBV Technologies' mission statement focuses on:

• Advancing pediatric food allergy treatment.
• Using innovative immunotherapy technologies.

The company's therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin®. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis.

DBV Technologies' food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV is commencing preparations for a BLA submission in the first half of 2026 to be supported by the Phase 3 VITESSE study, which is on-track for readout of topline results in the fourth quarter of 2025.

DBV Technologies is committed to transforming the care of food allergic people. DBV plans to explore a potential new class of immunotherapy to transform the lives of people with unmet medical needs.

The company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

DBV Technologies' long-term vision is to realize the full potential of the Viaskin™ Platform.

DBV Technologies S.A. integrates a set of core values into its operations, which are rooted in the DNA of the company:

• Courage: Taking smart risks and mentoring each other to always do better, pushing boundaries, turning challenges into opportunities, and being accountable for choices, opinions, and actions.
• Curiosity: Engaging in creative scientific exploration as part of a small but international team, and being responsible for major developments in service of patients.
• Collaboration: Working as part of an agile, fast-paced environment for people who are passionate about therapeutic advancements.
• Credibility: Giving the best to patients, stakeholders, and partners through transparency and expertise, where data and results matter most.

To gain more insights into DBV Technologies S.A. (DBVT) financial standing, here is a relevant resource: Breaking Down DBV Technologies S.A. (DBVT) Financial Health: Key Insights for Investors

DBV Technologies S.A. (DBVT) Vision Statement of

While direct access to DBV Technologies' official mission statement, vision, and core values as of April 2025 is unavailable, we can analyze their strategic goals, public statements, and activities to infer these elements. This approach allows us to understand the direction the company is heading.

Inferred Mission Statement

Based on their activities, a possible mission statement for DBV Technologies could be: 'To transform the lives of individuals with food allergies by pioneering innovative, safe, and effective epicutaneous immunotherapy (EPIT) solutions.' This reflects their focus on addressing food allergies with their unique technology.

Inferred Vision Statement

DBV Technologies' vision appears to be centered on becoming a leader in the food allergy treatment space, particularly through their EPIT platform. Key components of this vision include:

• Innovation in Allergy Treatment: DBV Technologies aims to revolutionize how food allergies are treated. Their EPIT platform, using Viaskin technology, represents a novel approach to immunotherapy.
• Improving Patient Outcomes: A core element of their vision is to enhance the quality of life for patients with food allergies. This involves developing treatments that are not only effective but also safe and convenient for patients.
• Global Accessibility: DBV Technologies likely envisions its products being available to patients worldwide. This requires strategic partnerships, regulatory approvals in various regions, and a robust supply chain.

In alignment with this vision, DBV Technologies has been actively pursuing clinical trials and regulatory approvals for its Viaskin Peanut patch. Although the company faced setbacks with the FDA's initial rejection of the Viaskin Peanut patch, they remain committed to addressing the needs of peanut-allergic children. In 2024, DBV Technologies reported a revenue of €9.6 million, primarily driven by research and development collaborations and a cash position of €149.1 million, highlighting their continued investment in future growth. You can read more about their financial health in this analysis: Breaking Down DBV Technologies S.A. (DBVT) Financial Health: Key Insights for Investors.

Inferred Core Values

DBV Technologies' core values are reflected in their commitment to scientific rigor, patient-centricity, and innovation. These values likely guide their decision-making and company culture.

• Innovation: DBV Technologies places a high value on innovation, as evidenced by their development of the EPIT platform and their ongoing research into new applications of this technology.
• Patient Focus: DBV Technologies is dedicated to improving the lives of patients with food allergies. This is reflected in their focus on developing treatments that are safe, effective, and convenient for patients.
• Scientific Rigor: DBV Technologies adheres to high scientific standards in their research and development activities. This is essential for ensuring the safety and efficacy of their products.

In summary, while the official mission statement, vision, and core values of DBV Technologies are not directly available, an analysis of their activities, goals, and values provides valuable insights into the company's strategic direction and priorities as of April 2025. Their focus remains on pioneering innovative solutions for food allergies, with the ultimate goal of improving patient outcomes on a global scale.

DBV Technologies S.A. (DBVT) Core Values of

While specific, formally published mission statements, vision statements, and core values for DBV Technologies S.A. (DBVT) as of April 2025 are not readily available in the provided search results, we can infer values and strategic directions from their activities, public statements, and overall business approach. These inferred values are based on the company's focus, actions, and objectives as observed through available information.

Patient-Centric Innovation

DBV Technologies appears to prioritize innovation with a strong focus on patient needs, particularly those with food allergies. This is evident in their development of Viaskin, a novel approach to treating allergies through epicutaneous immunotherapy (EPIT). Their commitment involves:

• Developing innovative solutions like Viaskin for food allergies.
• Focusing on EPIT to improve the safety and convenience of allergy treatments.
• Conducting clinical trials to validate the efficacy and safety of their products. For example, the Phase III trial of Viaskin Peanut showed promise in treating peanut allergies in young children.

Scientific Rigor and Integrity

A commitment to scientific rigor and integrity is crucial in the biotechnology industry. This is reflected in DBV Technologies' approach to clinical trials and regulatory submissions. Examples include:

• Adhering to strict scientific standards in the design and execution of clinical trials.
• Collaborating with leading researchers and institutions to advance scientific understanding of food allergies.
• Ensuring transparency and accuracy in reporting clinical trial results.

Collaboration and Partnership

DBV Technologies seems to value collaboration and partnership to enhance its research and development efforts. This includes:

• Collaborating with academic institutions and research organizations to expand its scientific knowledge base.
• Partnering with pharmaceutical companies to commercialize its products and expand its market reach.
• Engaging with patient advocacy groups to understand the needs of patients and their families.

Commitment to Quality and Safety

In the pharmaceutical industry, quality and safety are paramount. DBV Technologies demonstrates this through:

• Maintaining high standards of quality in the manufacturing of its products.
• Implementing rigorous safety protocols in clinical trials.
• Monitoring and reporting adverse events to ensure patient safety.

Focus on Regulatory Compliance

Navigating the regulatory landscape is critical for biotechnology companies. DBV Technologies emphasizes this by:

• Working closely with regulatory agencies like the FDA to obtain approval for its products.
• Ensuring compliance with all applicable laws and regulations.
• Maintaining open and transparent communication with regulatory authorities.

For more insights into DBV Technologies S.A. (DBVT), explore Exploring DBV Technologies S.A. (DBVT) Investor Profile: Who’s Buying and Why?